Plaque Psoriasis

A group of specialists discusses unmet needs in psoriatic disease including physician education about biologics and research about treatment options for pediatric patients, patients with malignancies, and patients who are pregnant.

Dr Lebwohl provides insight on a new class of agents, the TYK2 inhibitors.

Drs Kircik and Stein Gold address roflumilast and tapinarof as new topical agents for the management of plaque psoriasis.

Investigators observed that many patients with psoriasis are not actively seeing a primary care physician and would welcome management of their cardiovascular risk factors.

Matthew Brunner, MHS, PA-C, DFAAPA, highlights the most anticipated developments in the field of treating patients with plaque psoriasis.

Stratification of patients for the treatment of plaque psoriasis based on comorbidities and prior biologic experience.

Dr Lebwohl explains the contraindications for IL-23 inhibitors when using them to treat plaque psoriasis.

Dr Kircik discusses the mechanisms of action involving IL-17 inhibitors when using them as a first-line therapy for plaque psoriasis.

A panel of experts builds a lively discussion on the evolving treatment landscape in plaque psoriasis and highlights the emergence of IL-23 inhibitors as a new class of biologic agents.

Thought leaders in the management of plaque psoriasis share personal insights into factors to consider when treating patients with IL-23 inhibitors, including when to switch biologic agents.

Investigators believe drugs like etanercept and ustekinumab could reduce the risk of psoriatic arthritis in patients with moderate-to-severe chronic plaque psoriasis.

Advanced practice providers discuss scenarios in which they would consider switching between therapies when treating patients with plaque psoriasis.

Lakshi Aldredge, MSN, ANP-BC, DCNP, and Matthew Brunner, MHS, PA-C, DFAAPA share their personal experiences with using IL-23 inhibitors in treating patients with plaque psoriasis.

Mark Lebwohl, MD, and Jerry Bagel, MD, MS, review the currently available TNF-α and IL-12/23 inhibitors used to treat plaque psoriasis.

Spearheaded by Dr Bagel, the panel explores the role of phototherapy in the treatment of plaque psoriasis.

Mechanism of action and dosing of IL-23 inhibitors use to treat plaque psoriasis as explained by advanced practice providers.

IL-17 inhibitors and IL-12/23 inhibitors used in the treatment of plaque psoriasis.

The panel addresses their treatment practices and procedure when first seeing a patient with plaque psoriasis, as well as the role of topical therapy in this disease.

Leon Kircik, MD, and Jerry Bagel, MD, MS, explain their reasoning behind choosing whether a patient with plaque psoriasis is a candidate for either topical or systemic therapeutic agents.

Matthew Brunner, MHS, PA-C, DFAAPA, and Lakshi Aldredge, MSN, ANP-BC, DCNP, share their experiences with tumor necrosis factor (TNF) inhibitors in treating plaque psoriasis.

Matthew Brunner, MHS, PA-C, DFAAPA, and Lakshi Aldredge, MSN, ANP-BC, DCNP, discuss factors leading to transition from topical agents to oral systemic therapies for plaque psoriasis.

Matthew Brunner, MHS, PA-C, DFAAPA, and Lakshi Aldredge, MSN, ANP-BC, DCNP, review use of nonbiologic oral systemic agents (eg, apremilast, methotrexate, acitretin) in the management of plaque psoriasis.

Matthew Brunner, MHS, PA-C, DFAAPA, and Lakshi Aldredge, MSN, ANP-BC, DCNP, discuss the current role of topical medications as the standard of care for initial therapy in plaque psoriasis.

Linda F. Stein Gold, MD, delves into the psychosocial impacts of living with plaque psoriasis.

Mark Lebwohl, MD, and Jerry Bagel, MD, MS, provide an overview of the pathogenesis of and comorbidities associated with plaque psoriasis.